AdipoSeeds

AdipoSeeds Inc. is a Japan-based company specializing in the innovative production of platelets from adipose tissue, utilizing advanced mesenchymal stem cell technology to address global medical needs. Founded in 2016 and headquartered in Tokyo, Japan, AdipoSeeds Inc. focuses on the production of platelets from human fat tissue.

In January 2026, AdipoSeeds Inc. raised an undisclosed amount in venture funding from returning investor Daiwa Corporate Investment. The company's leadership details are currently unavailable. AdipoSeeds specializes in the innovative development of platelet production from adipose tissue, utilizing adipose-derived mesenchymal stem cells (ASC).

The company has established a groundbreaking technology that enables the culture of platelets without complex and costly gene introduction methods. This process allows for the extraction of platelets from human adipose tissue obtained through liposuction, ensuring a stable and consistent supply. The primary end-use cases include addressing the global shortage of platelets, particularly for medical treatments associated with bleeding disorders, surgical procedures, and injuries. AdipoSeeds’ products are aimed at hospitals, medical research institutions, and clinical settings primarily in Japan and are anticipated to expand into other global markets as the technology matures.

AdipoSeeds generates revenue through partnerships and collaborations with healthcare providers and research institutions that utilize its platelet production technology. These transactions are structured around licensing agreements, where clients gain access to the proprietary technology for clinical applications. Revenue is derived from these licensing fees, as well as potential royalties from products developed using AdipoSeeds' technology, including platelet-based treatments and regenerative medicine products. The company’s focus is on producing cost-effective solutions that enhance the availability of platelets, positioning itself as a partner in the healthcare ecosystem aimed at improving patient outcomes in various medical fields.

Specific pricing plans for services and products offered were not disclosed. In January 2026, AdipoSeeds Inc. raised an undisclosed amount in venture funding from returning investor Daiwa Corporate Investment. The comapny will use January 2026 funds to initiate domestic Phase I/II clinical trials for ADS-01, an allogeneic regenerative medicine product developed for treating intractable skin ulcers.